Frida Bugge Askeland

Dr. Frida Bugge Askeland


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2025 in The Lancet Haematology
Verified
Journal Article
Closed access
FAFrida Bugge Askeland
Frida Bugge Askeland
EHEinar Haukås
Einar Haukås
TSTobias S Slørdahl
Tobias S Slørdahl
AKAnja Klostergaard
Anja Klostergaard
TATatjana Alexandersen
Tatjana Alexandersen
FSFredrik Schjesvold
Fredrik Schjesvold

24 September 2020 in Hemato
Verified
Journal Article
Open access
PDF file
ARAnne-Marie Rasmussen
Anne-Marie Rasmussen
FAFrida Bugge Askeland
Frida Bugge Askeland
Fredrik SchjesvoldFredrik Schjesvold
Fredrik Schjesvold
The treatment approach for multiple myeloma (MM) has changed in recent years. After the approval of maintenance treatment after stem cell transplant in younger patients, the paradigm of continuous treatment is now prevailing in all clinical situations of myeloma. However, the best time to initiate relapse treatment is still unclear. With increased frequency of minimal residual disease (MRD) negativity, and the established clinical benefit of this finding, one of the large clinical questions in myeloma is how to approach MRD re-appearance. In this paper, we go through the MRD technology, existing and possible uses of MRD in the clinic, and data for early treatment before we introduce the design of the ongoing REMNANT study; a randomized study with early treatment of MRD relapse after first line treatment.

11 October 2024 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
FAFrida Bugge Askeland
Frida Bugge Askeland
HFHege M. Frøen
Hege M. Frøen
NBNils Bolstad
Nils Bolstad
PTPer Medbøe Thorsby
Per Medbøe Thorsby
FSFredrik Schjesvold
Fredrik Schjesvold
GTGeir Erland Tjonnfjord
Geir Erland Tjonnfjord

1 July 2020 in eJHaem
Verified
Journal Article
Open access
PDF file
NJNordberg Nørgaard Jakob
Nordberg Nørgaard Jakob
FAFrida Bugge Askeland
Frida Bugge Askeland
GTGeir Erland Tjonnfjord
Geir Erland Tjonnfjord
Fredrik SchjesvoldFredrik Schjesvold
Fredrik Schjesvold
Click on the article title to read more.

1 April 2026 in AME Clinical Trials Review
Verified
Journal Article
Open access
PDF file
FAFrida Bugge Askeland
Frida Bugge Askeland
FSFredrik Schjesvold
Fredrik Schjesvold
Response to “Steroid-Limited Isatuximab-Based Quadruplet Therapy in Elderly, Transplant-Ineligible Multiple Myeloma: A REST Trial Commentary”

22 December 2025 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
FAFrida Bugge Askeland
Frida Bugge Askeland
VBVilhelm Hauge Bugge
Vilhelm Hauge Bugge
ARAnne-Marie Rasmussen
Anne-Marie Rasmussen
ALAnna Lysén
Anna Lysén
EHEinar Haukås
Einar Haukås
Fredrik SchjesvoldFredrik Schjesvold
Fredrik Schjesvold
Renal impairment (RI) is a serious complication in multiple myeloma (MM), linked to poor survival and early mortality. Rapid renal recovery improves outcomes, yet patients with RI have been excluded from most key trials in transplant-eligible newly diagnosed (TE-ND) MM. REMNANT is an ongoing, academic, multicenter phase 2/3 study in TE-NDMM patients aged 18–75, regardless of baseline renal function. Here, we report a subanalysis of the non-randomized phase 2 component. All patients received four 21-day cycles of induction with bortezomib, lenalidomide, and dexamethasone. Lenalidomide was dosed higher than the recommended standard of care: 25 mg/day for eGFR ≥30 mL/min/1.73 m² and 15 mg/day for eGFR <30. Between August 2020 and September 2024, 382 patients were enrolled; 81 (21%) had RI, including seven (2%) on dialysis during cycle 1. Renal response was achieved in 77%, with complete renal response in 57%. Five dialysis-dependent patients became dialysis-independent. Overall response rates were similar, and adverse events were comparable between RI and non-RI groups, except for higher rates of anemia and thrombocytopenia in the RI cohort. Four RI patients (5%) experienced worsening renal function; two cases were possibly related to lenalidomide, both reversible. These findings support the safety and efficacy of increased lenalidomide-dosing during induction in TE-NDMM patients with RI, including those with severe impairment.